瘤学中的MEK抑制剂:专利审查和更新 (2016年至今)
Anjali Suryavanshi1, Vandana1, Yugal Kishor Shukla1
1Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India.
Expert opinion on therapeutic patents
|September 14, 2024
概括
线素激活蛋白激酶 (MEK) 抑制剂,特别是在组合疗法中,在治疗各种癌症方面显示出显著的希望. 这些有针对性的方法对抗耐药性或复发性恶性瘤特别有效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 线素激活蛋白激酶 (MEK) 在Ras/Raf/MEK/ERK通路中至关重要,调节细胞生长和发育.
- MEK放松管制与各种癌症有关,使其成为关键的治疗点.
- 目前正在探索MEK抑制剂用于癌症治疗,特别是在组合策略中.
研究的目的:
- 审查2016年至2024年5月在瘤学中使用MEK抑制剂的专利文献.
- 分析MEK抑制剂的组合产品和结构见解.
- 评估MEK抑制剂在各种恶性瘤中的治疗潜力.
主要方法:
- 进行全面的专利文献搜索 (2016-2024年).
- 搜索的数据库:PubMed,Scopus,Espacenet,科学网,世界知识产权组织,谷歌专利.
- 对MEK抑制剂,组合疗法和结构数据的分析.
主要成果:
- 与其他激酶抑制剂 (例如BRaf,Kras,PI3K) 结合的MEK抑制剂显示出显著的抗增殖活性.
- 与PD-1,EGFR,BTK和VEGF抑制剂的组合在结直肠,胰腺,乳腺癌,黑色素瘤和多发性髓瘤中显示出有前途.
- 双重或多重目标方法为耐药癌症提供了改进和精确的治疗方法.
结论:
- 在开发向癌症治疗中,MEK 抑制剂至关重要.
- 涉及MEK抑制剂的组合疗法在多种多样的耐药癌症中显示出增强的疗效.
- 未来的研究应该专注于优化这些多目标策略,以获得更好的患者结果.
关键词:
癌症 癌症 癌症 癌症这就是MEK MEK.临床试验是指临床试验中的临床试验.抑制剂的使用.突变是一种突变.patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent个性化医疗是个性化的医疗.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K